Valuation : ABIONYX Pharma SA

Market Cap 77.9M 90.42M 73.76M 66.86M 125M 8.64B 126M 876M 337M 4.39B 340M 332M 13.89B P/E 2026 *
-4.04x
P/E 2027 * -6.54x
Enterprise Value 74.2M 86.12M 70.26M 63.68M 119M 8.23B 120M 834M 321M 4.19B 323M 316M 13.23B EV / Sales 2026 *
15.9x
EV / Sales 2027 * 5.25x
Free-Float
85.31%
Yield 2026 *
-
Yield 2027 * -
1 day-2.08%
1 week-3.56%
Current month-8.21%
1 month-2.29%
3 months-32.58%
6 months-45.18%
Current year-48.19%
1 week 1.78
Extreme 1.78
1.85
1 month 1.78
Extreme 1.78
1.95
Current year 1.78
Extreme 1.776
4.02
1 year 1.78
Extreme 1.776
5
3 years 0.85
Extreme 0.854
5
5 years 0.85
Extreme 0.854
5
10 years 0.15
Extreme 0.15
8.42
Manager TitleAgeSince
Chief Executive Officer 49 2019-09-05
Director of Finance/CFO - -
Chief Operating Officer - 2005-12-31
Director TitleAgeSince
Director/Board Member 49 2019-09-05
Director/Board Member 52 2010-07-19
Director/Board Member 76 2015-02-05
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%-3.56% - - 90.42M
Average -2.08%
Weighted average by Cap. -2.08%

Financials

2026 *2027 *
Net sales 4.66M 5.41M 4.41M 4M 7.5M 517M 7.54M 52.4M 20.15M 263M 20.31M 19.87M 831M 14.77M 17.14M 13.98M 12.67M 23.78M 1.64B 23.9M 166M 63.86M 833M 64.37M 62.96M 2.63B
Net income -19.83M -23.01M -18.77M -17.02M -31.92M -2.2B -32.08M -223M -85.74M -1.12B -86.42M -84.52M -3.53B -12.92M -15M -12.24M -11.09M -20.81M -1.43B -20.91M -145M -55.88M -729M -56.33M -55.09M -2.3B
Net Debt -3.7M -4.29M -3.5M -3.18M -5.96M -410M -5.99M -41.61M -16M -209M -16.13M -15.77M -660M -400K -464K -379K -343K -644K -44.35M -647K -4.5M -1.73M -22.56M -1.74M -1.71M -71.3M
Logo ABIONYX Pharma SA
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2025, the company boasted a portfolio of 3 products in clinical development.
Employees
49
Date Price Change
26-09-11 €1.790 -2.08%
26-09-10 €1.828 +2.70%
26-09-09 €1.780 -1.33%
26-09-08 €1.804 -2.49%
26-09-07 €1.850 -0.32%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.840EUR
Average target price
10.50EUR
Spread / Average Target
+470.65%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!